Gabisof

Gabisof

gefitinib

Manufacturer:

Khandelwal Lab

Distributor:

Ni Lay Naing
Concise Prescribing Info
Contents
Gefitinib
Indications/Uses
Locally advanced or metastatic non-small cell lung cancer after failure of platinum-based & docetaxel chemotherapies.
Dosage/Direction for Use
Adult 250 mg once daily on continuous schedule over 28 days. May be given in 14 days on & 14 days off in patients w/ poorly tolerated diarrhea & skin adverse reaction.
Administration
May be taken with or without food: Do not crush/break. May disperse tab in ½ glass of noncarbonated drinking water w/o crushing until it disperses. Drink immediately, rinse glass w/ water & drink again. May be given via nasogastric tube.
Contraindications
Special Precautions
Not for new patients. Interrupt treatment in case of acute onset or worsening of pulmonary symptoms. Discontinue w/ confirmed interstitial lung disease. Monitor INR or prothrombin time regularly in patients receiving warfarin. Eye irritation. Cardiac disease. Hepatic & severe renal impairment. Pregnancy & lactation. Childn.
Adverse Reactions
Conjunctivitis; diarrhea, nausea, vomiting, anorexia; rash, acne, dry skin.
Drug Interactions
Increased metabolism & decreased plasma conc w/ CYP3A4 inducers (eg, rifampicin, phenytoin). Decreased metabolism & increased plasma conc w/ CYP3A4 inhibitors (eg, ketoconazole, itraconazole). Decreased plasma conc w/ H2-receptor antagonists (eg, ranitidine, cimetidine). Increases warfarin INR & bleeding events. Possible increased levels of ALP, ALT, AST & serum bilirubin.
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01EB01 - gefitinib ; Belongs to the class of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Used in the treatment of cancer.
Presentation/Packing
Form
Gabisof FC tab 250 mg
Packing/Price
10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in